Glaucoma After Iodine-125 Brachytherapy for Uveal Melanoma: Incidence and Risk Factors

被引:18
作者
Kim, Eun-Ah [1 ]
Salazar, Diana [1 ]
McCannel, Colin A. [1 ,2 ]
Kamrava, Mitchell [3 ]
Demanes, David J. [3 ]
Lamb, James [3 ]
Caprioli, Joseph [1 ]
McCannel, Tara A. [1 ,2 ]
机构
[1] Univ Calif Los Angeles, Stein Eye Inst, 100 Stein Plaza, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Dept Ophthalmol, Doheny Eye Inst, Los Angeles, CA USA
[3] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiat Oncol, Los Angeles, CA 90095 USA
关键词
uveal melanoma; brachytherapy; iodine-125; secondary open-angle glaucoma; neovascular glaucoma; OPEN-ANGLE GLAUCOMA; PROTON-BEAM THERAPY; SILICONE OIL; PLAQUE BRACHYTHERAPY; NEOVASCULAR GLAUCOMA; CHOROIDAL MELANOMA; IODINE-125; BRACHYTHERAPY; INTRAOCULAR-PRESSURE; OCULAR COMPLICATIONS; VITRECTOMY;
D O I
10.1097/IJG.0000000000001393
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Precis: A single-center retrospective review over a 10-year period discovered an 8.6% risk of developing secondary open-angle glaucoma, and a 6.7% risk of neovascular glaucoma after brachytherapy for uveal melanoma. Additional risk factors were identified. Purpose: To report the incidence and identify risk factors for secondary open-angle glaucoma and neovascular glaucoma after iodine-125 brachytherapy for uveal melanoma in a tertiary ocular oncology and glaucoma practice. Patients and Methods: Eyes of patients who had been diagnosed and treated with iodine-12 brachytherapy for uveal melanoma over a 10-year period were included for review. Secondary open-angle glaucoma was defined as meeting the following criteria: at least 3 measurements of intraocular pressure (IOP) >= 21 mm Hg after the removal of the iodine-125 plaque and an open angle on gonioscopy. Neovascular glaucoma was defined as meeting the following criteria: at least 3 measurements of IOP >= 21 mm Hg and neovascularization of the iris or anterior chamber angle. Cumulative incidence was calculated and survival analysis was used to analyze risk factors for both secondary open-angle glaucoma and neovascular glaucoma. Results: A total of 374 eyes in patients diagnosed with uveal melanoma and treated with Iodine-125 brachytherapy were included in the study. Thirty-one eyes (8.6%) were diagnosed with secondary open-angle glaucoma and 25 eyes (6.7%) were diagnosed with neovascular glaucoma. Multivariate analysis identified the following risk factors for secondary open-angle glaucoma: older age, greater tumor size, iris location of uveal melanoma, higher baseline IOP, ciliary body involvement, and eyes having undergone combined brachytherapy with vitrectomy and silicone oil placement for radiation attenuation. The risk factors for neovascular glaucoma were as follows: greater tumor size, greater number of pack-years smoking history, pseudophakia, and higher grade of radiation retinopathy severity by fluorescein angiogram. Conclusions: We have identified additional risk factors for the development of both secondary open-angle glaucoma and neovascular glaucoma in patients with uveal melanoma who have undergone iodine-125 brachytherapy for local tumor control. The risk of secondary glaucoma is substantial. Close ophthalmic monitoring of patients is necessary for detection and timely treatment of glaucoma to maximize visual outcome.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 44 条
[1]  
[Anonymous], 1990, ARCH OPHTHALMOL-CHIC, V108, P1268, DOI DOI 10.1001/ARCHOPHT.1990.01070110084030
[2]  
APPLE DJ, 1984, OPHTHALMOLOGY, V91, P403
[3]   Iodine 125 plaque brachytherapy versus transscleral tumor resection in the treatment of large uveal melanomas [J].
Bechrakis, NE ;
Bornfeld, N ;
Zöller, I ;
Foerster, MH .
OPHTHALMOLOGY, 2002, 109 (10) :1855-1861
[4]  
Bhatia SK, 2011, ARCH OPHTHALMOL-CHIC, V129, P668, DOI 10.1001/archophthalmol.2011.94
[5]   Risk factors and open-angle glaucoma: Classification and application [J].
Boland, Michael V. ;
Quigley, Harry A. .
JOURNAL OF GLAUCOMA, 2007, 16 (04) :406-418
[6]   Intraoperative Ultrasonography-Guided Positioning of Iodine 125 Plaque Brachytherapy in the Treatment of Choroidal Melanoma [J].
Chang, Melinda Y. ;
Kamrava, Mitchell ;
Demanes, D. Jeffrey ;
Leu, Min ;
Agazaryan, Nzhde ;
Lamb, James ;
Moral, Joel N. ;
Almanzor, Robert ;
McCannel, Tara A. .
OPHTHALMOLOGY, 2012, 119 (05) :1073-1077
[7]  
COGAN DG, 1952, AMA ARCH OPHTHALMOL, V47, P55
[8]  
Collaborative Ocular Melanoma Grp, 2006, ARCH OPHTHALMOL-CHIC, V124, P1684
[9]   Iris and anterior chamber angle neovascularization after iodine 125 brachytherapy for uveal melanoma [J].
Detorakis, ET ;
Engstrom, RE ;
Wallace, R ;
Straatsma, BR .
OPHTHALMOLOGY, 2005, 112 (03) :505-510
[10]  
Diener-West M, 2001, ARCH OPHTHALMOL-CHIC, V119, P969